ATE265220T1 - Kostimulatorische blockade und gemischter chimerismus in allotransplantationen - Google Patents

Kostimulatorische blockade und gemischter chimerismus in allotransplantationen

Info

Publication number
ATE265220T1
ATE265220T1 AT99905798T AT99905798T ATE265220T1 AT E265220 T1 ATE265220 T1 AT E265220T1 AT 99905798 T AT99905798 T AT 99905798T AT 99905798 T AT99905798 T AT 99905798T AT E265220 T1 ATE265220 T1 AT E265220T1
Authority
AT
Austria
Prior art keywords
allotransplants
mixed chimerism
costimulatory blockade
blockade
costimulatory
Prior art date
Application number
AT99905798T
Other languages
English (en)
Inventor
Megan Sykes
Mohamed H Sayegh
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE265220T1 publication Critical patent/ATE265220T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Artificial Fish Reefs (AREA)
AT99905798T 1998-02-04 1999-02-04 Kostimulatorische blockade und gemischter chimerismus in allotransplantationen ATE265220T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7386498P 1998-02-04 1998-02-04
PCT/US1999/002542 WO1999039727A1 (en) 1998-02-04 1999-02-04 Costimulatory blockade and mixed chimerism in allotransplantation

Publications (1)

Publication Number Publication Date
ATE265220T1 true ATE265220T1 (de) 2004-05-15

Family

ID=22116269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905798T ATE265220T1 (de) 1998-02-04 1999-02-04 Kostimulatorische blockade und gemischter chimerismus in allotransplantationen

Country Status (9)

Country Link
US (3) US6280957B1 (de)
EP (2) EP1058555B1 (de)
JP (2) JP2002502823A (de)
AT (1) ATE265220T1 (de)
AU (2) AU748443B2 (de)
CA (2) CA2319448A1 (de)
DE (1) DE69916807T2 (de)
IL (2) IL137614A0 (de)
WO (2) WO1999039726A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6006752A (en) * 1996-05-09 1999-12-28 The General Hospital Corporation Mixed chimerism and tolerance
CN1360596A (zh) * 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
AU5641100A (en) * 1999-06-29 2001-01-31 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20010046489A1 (en) * 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
WO2001068134A2 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
MXPA03006699A (es) * 2001-01-26 2004-05-31 Univ Emory Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
EP1549277A4 (de) * 2002-05-22 2007-09-05 Cleveland Clinic Foundation Einleitung und aufrechterhaltung von toleranz gegenüber zusammengesetzten gewebe-allotransplantaten
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
EP1658096A1 (de) * 2003-08-25 2006-05-24 PanGenetics B.V. Verfahren zur auslösung von immuntoleranz
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance
EP2338511A3 (de) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Verlängerung der Überlebungszeit eines Allografts durch Hemmung der Komplementsaktivität
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
SG10202001007TA (en) 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
BRPI0708424A2 (pt) 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
WO2011146395A2 (en) * 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
TW201244737A (en) 2011-02-03 2012-11-16 Alexion Pharma Inc Use of an anti-CD200 antibody for prolonging the survival of allografts
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
CN113476478A (zh) 2013-02-26 2021-10-08 小利兰·斯坦福大学托管委员会 实现移植物移植耐受的联合器官和造血细胞
EP3033093A1 (de) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Behandlung von transplantatabstossung durch verabreichung eines komplementinhibitors an ein organ vor der transplantation
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
EP3765044A4 (de) 2018-03-12 2021-12-08 Medeor Therapeutics, Inc. Verfahren zur behandlung von nichtkanzerösen erkrankungen unter verwendung von hämatopoetischen zellen
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
AU2022205313A1 (en) * 2021-01-06 2023-07-20 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
AU679437B2 (en) 1992-01-08 1997-07-03 General Hospital Corporation, The Induced tolerance to xenografts
WO1994026289A1 (en) 1992-02-19 1994-11-24 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5869049A (en) 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
CA2191733A1 (en) 1994-06-07 1995-12-21 Daniel A. Vallera Methods for inhibiting antigen specific t cell responses
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
US6006752A (en) 1996-05-09 1999-12-28 The General Hospital Corporation Mixed chimerism and tolerance
DE69731836T2 (de) 1996-07-23 2005-12-01 Pangenetics B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann

Also Published As

Publication number Publication date
IL137614A0 (en) 2001-07-24
EP1058555B1 (de) 2004-04-28
WO1999039726A1 (en) 1999-08-12
US6514513B1 (en) 2003-02-04
CA2319764A1 (en) 1999-08-12
EP1053006A1 (de) 2000-11-22
AU2588099A (en) 1999-08-23
JP2002502824A (ja) 2002-01-29
WO1999039727A1 (en) 1999-08-12
DE69916807D1 (de) 2004-06-03
JP2002502823A (ja) 2002-01-29
AU746825B2 (en) 2002-05-02
AU2583999A (en) 1999-08-23
US20020055122A1 (en) 2002-05-09
CA2319448A1 (en) 1999-08-12
EP1058555A1 (de) 2000-12-13
EP1053006A4 (de) 2002-09-25
AU748443B2 (en) 2002-06-06
EP1058555A4 (de) 2001-02-28
US6280957B1 (en) 2001-08-28
IL137361A0 (en) 2001-07-24
DE69916807T2 (de) 2005-01-13

Similar Documents

Publication Publication Date Title
DE69916807D1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
ES2195664T3 (es) Uso de fumaratos de dialquilo.
ES2194106T3 (es) .ompuestos de imidazol
TR200103216T2 (tr) Pirimidinon bileşimleri
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ES2300276T3 (es) P40 de interleuquina-12 de mamifero e interleuquina b30. sus combinaciones. anticuerpos. usos en composiciones farmaceuticas.
ATE233735T1 (de) Neue phenanthridine
DK0733109T3 (da) BMP-12, BMP-13 og seneinducerende præparater dermed
PT935465E (pt) Compostos novos de imidazole substituido
NZ527076A (en) Graft rejection inhibitors used in combination with immunosuppressants
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE69731400D1 (de) Proliferation humaner endokriner pankreaszellen in kultur
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
FR2749022B1 (fr) Cellules aviaires immortelles
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
NO20031860D0 (no) Kahalaolid F
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
IS4915A (is) Samsetningar sem innihalda VX478, Zídóvúdín, FTC og/eða 3TC til að nota við meðhöndlunina á HIV
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
NO20005667D0 (no) Meioseregulerende forbindelser
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
HUP0101393A1 (hu) Redukáló körülményekre érzékeny transzfektáló kompozíciók, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE221388T1 (de) Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties